Ogilvies syndrom

What is Ogilvie's syndrome?

Ogilvie's syndrome is a syndrome of acute intestinal pseudo-obstruction associated with massive dilation, usually of the colon but also of the small intestine. Mechanical obstruction is absent and there is parasympathetic nerve dysfunction. It was first described by Sir William Heneage Ogilvie in 1948, an English surgeon. The syndrome is also known as acute colonic pseudo-obstruction (ACPO).¹

Acute colonic distension is a medical emergency with high morbidity and mortality.²

How common is Ogilvie's syndrome? (Epidemiology)

• It is a rare condition and the incidence rate is not actually known.

• Oglivie's syndrome is more common in the elderly.

Riskfaktorer

Oglivie's syndrome is often associated with other conditions, including:³

• Recent obstetric, gynaecological or pelvic surgery.

• Recent trauma or orthopaedic procedure.

• Underlying infection.

• Recent cardiac events.

• Electrolyte imbalance.

• Medications (eg, opioids, antidepressants).

• Solid organ transplant.

Ogilvie's syndrome symptoms

Although symptoms and signs of a large bowel obstruction commonly occur, Oglivie's syndrome can have a variable clinical presentation. It is important therefore to have a high degree of suspicion.

Symptom

• Abdominal pain, usually cramping or colicky.

• Bloated feeling.

• Illamående och kräkningar.

• Intermittent constipation.

Skyltar

• Massive abdominal distension.

• Normal, reduced or obstructed bowel sounds.

• Minimal tenderness.

• Empty, air-filled rectum on digital rectal examination.

If left unrecognised, progressive dilatation of the colon can result in mural ischemia, perforation, acute peritonitis, and increased mortality.³

Differentialdiagnos

• Mechanical obstruction.

• Colonic adenocarcinoma.

• Scarring, adhesions.

• Inflammatory conditions - peptic ulcer, appendicit, pancreatitis.

• Irritabel tarm.

• Hirschsprungs sjukdom.

• Parasitic infection - eg, Amerikansk trypanosomiasis.

Utredningar

• Full history - symptoms, drug history, previous surgery, past medical history and family history, psychiatric history, habits and normal diet.

• Full examination - to identify other conditions and including digital rectal examination.

• Abdominal X-ray often shows massive dilation of the colon (megacolon) with caecal diameters measuring 10-14 cm.

• A CT scan is often undertaken to exclude a mechanical obstruction.

Ogilvie's syndrome treatment and management⁴

Timely recognition and close monitoring are extremely important in the management of this condition. The majority of patients improve with conservative measures.

Allmänna åtgärder

• If possible, treat the cause.

• Enable the patient to be mobile and, if possible, to exercise.

• Advise adequate fluid intake.

• Nasogastric tube to decompress the stomach and relieve vomiting.

Farmakologisk

• Antiemetic prokinetics - eg, metoclopramide.

• Intravenous (IV) neostigmine is often given and it is a safe and effective option for patients with Oglivie's syndrome who fail to respond to conservative management.⁵ When given as a bolus it can lead to a rapid improvement.⁶

• Intravenous fluids.

• Antibiotics are started if an underlying infection is suspected.

Kirurgisk

• Perforation, ischaemia and peritonitis necessitate urgent surgical intervention.³

• Decompression with flexible colonoscope, especially when caecal dilatation reaches dimensions that are considered a high risk for perforation.¹

• Surgery undertaken is usually a caecostomy or colectomy.

• Laparotomy is indicated for ischaemia and perforation, or if the diagnosis is not clear.

Prognos

Acute colonic distension has a high morbidity and mortality. Patients avoiding surgery and perforation make good recovery generally, although recurrence is common.²

The age of the patient, maximal caecal diameter and delay in colonic decompression have been shown to have a significant direct correlation to mortality.³

Surgery is associated with high rates of morbidity and mortality.¹

Förebyggande

• Avoidance of bed rest.

• Adequate hydration.

• Avoidance of drugs which inhibit parasympathetic gastrointestinal muscle action.